Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
ACADIA Pharmaceuticals Inc Market Cap
Based on ratings from 15 stock analysts, the ACADIA Pharmaceuticals Inc stock price is expected to increase by 42.17% in 12 months. This is calculated by using the average 12-month stock price forecast for ACADIA Pharmaceuticals Inc. The lowest target is $25.00 and the highest is $42.00. Please note analyst price targets are not guaranteed and could be missed completely.
ACAD is a stock in Health Care which has been forecasted to be worth $35.33 as an average. On the higher end, the forecast price is $42.00 USD by sarah james from Cantor Fitzgerald and on the lower end ACAD is forecasted to be $25.00 by michael higgins from Ladenburg Thalmann & Co..
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| jay olson Oppenheimer | Hold | $25.0 | maintained | Feb 4, 2024 |
| paul matteis Stifel Nicolaus | Hold | $27.0 | maintained | Dec 18, 2023 |
| tazeen ahmad Bank of America Securities | Hold | $33.0 | reiterated | Dec 14, 2023 |
| neena bitritto garg Deutsche Bank | Hold | $25.0 | downgraded | Dec 13, 2023 |
| julio romero Sidoti | Hold | $21.0 | maintained | Mar 20, 2023 |
| esther hong Loop Capital Markets | Hold | $20.0 | maintained | Feb 27, 2023 |
| danielle brill Raymond James | Hold | None | maintained | Feb 27, 2023 |
| cory kasimov J.P. Morgan | Hold | $19.0 | downgraded | Jun 21, 2022 |
| vamil divan Mizuho Securities | Hold | $27.0 | rated | Jun 17, 2022 |
| pito chickering Deutsche Bank | Hold | $62.0 | maintained | Apr 19, 2021 |
| alan carr Needham | Hold | None | rated | Feb 1, 2021 |
| scott henry Roth Capital | Hold | $25.0 | reiterated | Jan 19, 2017 |
| michael higgins Ladenburg Thalmann & Co. | Hold | $25.0 | reiterated | Nov 28, 2016 |
| robert leboyer Noble Financial | Hold | $41.0 | downgraded | Aug 5, 2016 |
| stephen biggar Argus Research | Hold | $35.0 | downgraded | May 3, 2016 |
| george zavoico B.Riley Financial | Hold | $20.0 | downgraded | Aug 7, 2013 |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
When did it IPO
2004
Staff Count
580
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Stephen R. Davis J.D.
Market Cap
$4.08B
In 2023, ACAD generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ACAD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
MRTX-USD
$58.7
AVT-USD
$46.44
FOLD-USD
$13.56
$48.92
IPGP-USD
$86.28
POWI-USD
$73.35
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
